Á¦2ȸ ¾ÆÁִ뺴¿ø ÀÎÇöó¸ÞÀÌ¡ Áß°³ÀÇÇÐ ±¹Á¦ ¾Ï ¿¬±¸ ½ÉÆ÷Áö¿ò : 2023-06-16
±³À°ÀÏÀÚ : 2023-06-16
±³À°Àå¼Ò : ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç
±³À°ÁÖÁ¦ : Á¦2ȸ ¾ÆÁִ뺴¿ø ÀÎÇöó¸ÞÀÌ¡ Áß°³ÀÇÇÐ ±¹Á¦ ¾Ï ¿¬±¸ ½ÉÆ÷Áö¿ò
ÁÖÃÖ±â°ü : ¾ÆÁÖ´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾ÆÁÖ´ëÇб³º´¿ø
´ã´çÀÚ : Çã¹Î¿µ
¿¬¶ôó : 031-219-7875
À̸ÞÀÏ : myheo3956@naver.com
±³À°Á¾·ù : ¿Ü°ú, »ýÈÇÐ
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : °æ±âµµ
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 16ÀÏ ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç 13:40~14:20 Targeting KRAS in pancreatic cancer. David A. Tuveson(Cancer Center, Cold Spring Harbor Laboratory, USA)
±³À°½Ã°£ 06¿ù 16ÀÏ ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç 14:20~14:45 New clasification for gastric cancer in the era of immuno-oncology ÇãÈÆ(¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç)
±³À°½Ã°£ 06¿ù 16ÀÏ ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç 14:45~15:05 Integrative Analysis of Single-Cell Transcriptomic Data in Cancer Research ÀÓ¼öºó(¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ »ýÈÇб³½Ç)
±³À°½Ã°£ 06¿ù 16ÀÏ ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç 15:25~16:00 Mesothelial-mesenchymal transition induced mesothelial cells enhance peritoneal dissemination through forming protumorigenic microenvironment Prof. Ishimoto(±¸¸¶¸ðÅä ´ëÇÐ)
±³À°½Ã°£ 06¿ù 16ÀÏ ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç 16:00~16:30 Cancer research models using patient-derived xenograft (PDX), patient-derived organoid (PDO) and PDX-derived organoid (PDXO) ±èÁ¾ÀÏ(¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ »ýÈÇб³½Ç)
±³À°½Ã°£ 06¿ù 16ÀÏ ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç 16:30~16:55 Senescent tumor cells; The new cancer microenvironment modulator ¹ÚÅÂÁØ(¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ »ýÈÇб³½Ç)
Åä·Ð 06¿ù 16ÀÏ ¾ÆÁÖ´ëÇб³º´¿ø º°°ü B1Ãþ ´ë°´ç 16:55~17:00 ÁúÀÇ ÀÀ´ä Tuveson, ÇãÈÆ, ÀÓ¼öºó, Ishimoto, ±èÁ¾ÀÏ, ¹ÚÅÂÁØ(¾ÆÁִ뺴¿ø, ¼¿ï´ëº´¿ø, ±¸¸¶¸ðÅä ´ëÇÐ, AACR)